The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is rapidly degraded in the circulation by dipeptidyl peptidase IV forming the N-terminally truncated peptide GIP(3-42). The present study examined the biological activity of this abundant circulating fragment peptide to establish its possible role in GIP action. Human GIP and GIP(3-42) were synthesised by Fmoc solid-phase peptide synthesis, purified by HPLC and characterised by electrospray ionisation-mass spectrometry. In GIP receptor-transfected Chinese hamster lung fibroblasts, GIP(3-42) dose dependently inhibited GIP-stimulated (10(-7) M) cAMP production (up to 75.4+/-5.4%; P<0.001). In BRIN-BD11 cells, GIP(3-42) was significantly less potent at stimulating insulin secretion (1.9- to 3.2-fold; P<0.001), compared with native GIP and significantly inhibited GIP-stimulated (10(-7) M) insulin secretion with maximal inhibition (48.8+/-6.2%; P<0.001) observed at 10(-7) M. In (ob/ob) mice, administration of GIP(3-42) significantly inhibited GIP-stimulated insulin release (2.1-fold decrease; P<0.001) and exaggerated the glycaemic excursion (1.4-fold; P<0.001) induced by a conjoint glucose load. These data indicate that the N-terminally truncated GIP(3-42) fragment acts as a GIP receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.

This article has been cited by other articles:

				C. Parthier, M. Kleinschmidt, P. Neumann, R. Rudolph, S. Manhart, D. Schlenzig, J. Fanghanel, J.-U. Rahfeld, H.-U. Demuth, and M. T. Stubbs Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor PNAS, August 28, 2007; 104(35): 13942 - 13947. [Abstract] [Full Text] [PDF]

				D. J. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action Diabetes Care, June 1, 2007; 30(6): 1335 - 1343. [Full Text] [PDF]

				F. P. M. O'Harte, K. Hunter, V. A. Gault, N. Irwin, B. D. Green, B. Greer, P. Harriott, C. J. Bailey, and P. R. Flatt Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1674 - E1682. [Abstract] [Full Text] [PDF]

				R K. Campbell Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60. [Abstract] [Full Text] [PDF]

				Y. Yamada, K. Miyawaki, K. Tsukiyama, N. Harada, C. Yamada, and Y. Seino Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide Diabetes, December 1, 2006; 55(Supplement_2): S86 - S91. [Abstract] [Full Text] [PDF]

				J. C. Parker, K S Lavery, N Irwin, B D Green, B Greer, P Harriott, F P M O'Harte, V A Gault, and P R Flatt Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol., October 1, 2006; 191(1): 93 - 100. [Abstract] [Full Text] [PDF]

				C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475. [Abstract] [Full Text] [PDF]

				I. Alana, J. C. Parker, V. A. Gault, P. R. Flatt, F. P. M. O'Harte, J. P. G. Malthouse, and C. M. Hewage NMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water J. Biol. Chem., June 16, 2006; 281(24): 16370 - 16376. [Abstract] [Full Text] [PDF]

				N. Irwin, B. D. Green, M. H. Mooney, B. Greer, P. Harriott, C. J. Bailey, V. A. Gault, F. P. M. O'Harte, and P. R. Flatt A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1187 - 1194. [Abstract] [Full Text] [PDF]

				B. D Green, N. Irwin, V. A Gault, F. P. O'Harte, and P. R Flatt Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 134 - 140. [Abstract] [PDF]

				J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]